Stockreport

FDA grants accelerated review for Merck's Keytruda for first-line lung cancer, action date October 30 [Seeking Alpha]

Merck & Company, Inc. (new)  (MRK) 
Last merck & company, inc. (new) earnings: 4/28 06:45 am Check Earnings Report
US:NYSE Investor Relations: investors.merck.com/home/default.aspx
PDF FDA grants accelerated review for Merck's Keytruda for first-line lung cancer, action date October 30The FDAaccepts under Priority Review status Merck's (NYSE:MRK) marke [Read more]